In patients with progressing CLL, BTK and PLCG2 mutations are often found in clones/subclones of variable size with reported ranges between 0.2% and nearly 100% [11,31,32,33,34]. The gene discussed is PLCG2; the disease is B-cell chronic lymphocytic leukemia.